A global survey of health professionals, led by Queen Mary University of London, has shown that during the COVID-19 pandemic, patients with Parkinson’s disease in large parts of Asia, Africa, and Latin and South America experienced difficulty in accessing their medication, which is likely to have led to deterioration of symptom control.
The email survey of the Movement Disorders Society, conducted in June 2020 at the height of the pandemic, received 346 responses from members in 76 countries. Responses indicated that 88.9% of those in low-income countries considered access to Parkinson’s disease medication to have been affected by COVID-19, compared with 22.8% of those in high income countries. All of the surveyed health professionals in low income countries indicated that this would result in increased disability. Resource-poor countries appear to be disproportionately affected compared with more affluent countries.
Source: Read Full Article